293 related articles for article (PubMed ID: 19247201)
1. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
[TBL] [Abstract][Full Text] [Related]
3. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
[TBL] [Abstract][Full Text] [Related]
4. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
Lencioni R; Marrero J; Venook A; Ye SL; Kudo M
Int J Clin Pract; 2010 Jul; 64(8):1034-41. PubMed ID: 20642705
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH
J Clin Oncol; 2010 May; 28(14):2323-30. PubMed ID: 20368568
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment.
Okusaka T; Otsuka T; Ueno H; Mitsunaga S; Sugimoto R; Muro K; Saito I; Tadayasu Y; Inoue K; Loembé AB; Ikeda M
Cancer Sci; 2016 Dec; 107(12):1791-1799. PubMed ID: 27627050
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Minami H; Kawada K; Ebi H; Kitagawa K; Kim YI; Araki K; Mukai H; Tahara M; Nakajima H; Nakajima K
Cancer Sci; 2008 Jul; 99(7):1492-8. PubMed ID: 18477034
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
Huang WS; Yang CH
World J Gastroenterol; 2009 Sep; 15(35):4464-6. PubMed ID: 19764104
[TBL] [Abstract][Full Text] [Related]
9. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
Zhu AX; Finn RS; Mulcahy M; Gurtler J; Sun W; Schwartz JD; Dalal RP; Joshi A; Hozak RR; Xu Y; Ancukiewicz M; Jain RK; Nugent FW; Duda DG; Stuart K
Clin Cancer Res; 2013 Dec; 19(23):6614-23. PubMed ID: 24088738
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives.
Trojan J
Drugs; 2020 Aug; 80(12):1203-1210. PubMed ID: 32671719
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study.
Kobayashi K; Ogasawara S; Maruta S; Okubo T; Itokawa N; Haga Y; Seko Y; Moriguchi M; Watanabe S; Shiko Y; Takatsuka H; Kanzaki H; Koroki K; Inoue M; Nakamura M; Kiyono S; Kanogawa N; Kondo T; Suzuki E; Ooka Y; Nakamoto S; Inaba Y; Ikeda M; Okabe S; Morimoto N; Itoh Y; Nakamura K; Ito K; Azemoto R; Atsukawa M; Itobayashi E; Kato N
Clin Cancer Res; 2023 Dec; 29(23):4760-4769. PubMed ID: 37796614
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.
Finkelmeier F; Scheiner B; Leyh C; Best J; Fründt TW; Czauderna C; Beutel A; Bettinger D; Weiß J; Meischl T; Kütting F; Waldschmidt DT; Radu P; Schultheiß M; Peiffer KH; Ettrich TJ; Weinmann A; Wege H; Venerito M; Dufour JF; Lange CM; Pinter M; Waidmann O
Liver Cancer; 2021 Jul; 10(4):360-369. PubMed ID: 34414123
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib.
Roderburg C; Bubenzer J; Spannbauer M; do O N; Mahnken A; Ludde T; Trautwein C; Tischendorf JJ
World J Hepatol; 2010 Jun; 2(6):239-42. PubMed ID: 21161003
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives.
Hsu CH; Shen YC; Shao YY; Hsu C; Cheng AL
J Hepatocell Carcinoma; 2014; 1():85-99. PubMed ID: 27508178
[TBL] [Abstract][Full Text] [Related]
15. Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis.
El Hajra I; Sanduzzi-Zamparelli M; Sapena V; Muñoz-Martínez S; Mauro E; Llarch N; Iserte G; Forner A; Rios J; Bruix J; Reig M
Hepatology; 2023 Apr; 77(4):1139-1149. PubMed ID: 36632997
[TBL] [Abstract][Full Text] [Related]
16. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.
Hernandez-Gea V; Toffanin S; Friedman SL; Llovet JM
Gastroenterology; 2013 Mar; 144(3):512-27. PubMed ID: 23313965
[TBL] [Abstract][Full Text] [Related]
17. Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States.
Parsons HM; Chu Q; Karlitz JJ; Stevens JL; Harlan LC
Liver Cancer; 2017 Jun; 6(3):216-226. PubMed ID: 29234628
[TBL] [Abstract][Full Text] [Related]
18. Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials.
Di Maio M; Daniele G; Piccirillo MC; Giordano P; Signoriello G; Daniele B; Perrone F
Cancers (Basel); 2012 Jun; 4(2):549-65. PubMed ID: 24213324
[TBL] [Abstract][Full Text] [Related]
19. A multicenter retrospective analysis: Factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancer.
Zou R; Hao Y; Wang Y; Yan F; Peng X; Huang Z; Chen G
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1918. PubMed ID: 38073600
[TBL] [Abstract][Full Text] [Related]
20. First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation.
von Felden J; Schulze K; Gil-Ibanez I; Werner T; Wege H
Diagnostics (Basel); 2016 Nov; 6(4):. PubMed ID: 27916795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
